Welcome to our dedicated page for Oric Pharmaceuticals SEC filings (Ticker: ORIC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ORIC Pharmaceuticals, Inc. filings document a Nasdaq-listed clinical-stage oncology company focused on therapeutic resistance in cancer. Its 8-K reports furnish financial results and operational updates, clinical presentation materials for rinzimetostat (ORIC-944) and enozertinib (ORIC-114), and Regulation FD investor presentation slides.
Other disclosures cover ORIC's common stock, shelf registration and at-the-market share sales, prospectus supplement activity, emerging growth company status, and annual meeting proxy matters. The proxy record addresses stockholder voting, board governance, compensation oversight, and equity incentive arrangements, including inducement grants under Nasdaq listing rules.
ORIC Pharmaceuticals reported continued clinical progress while strengthening its balance sheet. Cash, cash equivalents and investments totaled $327.7 million as of June 30, 2025, and management believes available resources are sufficient to fund operations into the second half of 2028. The company reported a net loss of $66.4 million for the six months ended June 30, 2025 and an accumulated deficit of $629.2 million.
Clinical updates include ORIC-944 combination data showing a 59% PSA50 response rate (47% confirmed) and 24% PSA90 (all confirmed) in mCRPC, and ORIC-114 advancing with provisional RP2D levels of 80 mg and 120 mg and reported intracranial activity. Financing activity included a $125.0 million private placement closed May 29, 2025, ATM proceeds of $8.9 million through June 30, 2025 and subsequent ATM net proceeds of approximately $108.7 million through August 12, 2025. On August 12, 2025, the company announced a strategic pipeline prioritization that will eliminate its discovery research group, reduce workforce by approximately 20% and incur an estimated one-time cost of $1.9 million.
ORIC Pharmaceuticals issued a press release reporting results for the quarter ended June 30, 2025 and announced a strategic pipeline prioritization to concentrate resources on its two lead clinical programs, ORIC-944 and ORIC-114. As part of the refocus, the company will eliminate its discovery research group, reducing headcount by approximately 20%.
The company expects a one-time charge of approximately $1.9 million, primarily for termination and healthcare-related benefits, with the workforce reduction substantially complete and the majority of related charges to be recognized in the third quarter of 2025. The company noted these estimates are subject to assumptions and may change.
Oric Pharmaceuticals CFO Dominic Piscitelli executed significant stock sales on June 23-24, 2025, through a pre-planned Rule 10b5-1 trading plan established on December 30, 2024. The transactions included:
- June 23: Sale of 584 shares at $10.00 and 450 shares at $10.01
- June 24: Sale of 32,466 shares at weighted average price of $10.5045 (range $10.34-$10.80)
Following these transactions, Piscitelli's direct ownership decreased from 101,233 to 68,317 shares, representing a roughly 32.5% reduction in his holdings. The sales were executed according to a predetermined trading plan, which helps avoid concerns about insider trading by establishing sale parameters in advance. The transactions demonstrate significant insider selling activity by a key executive officer.
ORIC Pharmaceuticals has filed a 424B3 prospectus for the resale of up to 19,230,845 shares of common stock by selling stockholders. This includes 14,130,313 outstanding shares and 5,100,532 shares issuable upon exercise of pre-funded warrants from a May 2025 private placement that raised approximately $125 million at $6.50 per share.
The company is advancing two key clinical-stage candidates:
- ORIC-944: A PRC2 inhibitor for prostate cancer, showing promising Phase 1b results. Currently in combination trials with apalutamide and darolutamide. Phase 3 trial planned for H1 2026.
- ORIC-114: A brain-penetrant EGFR/HER2 inhibitor for solid tumors, demonstrating both systemic and intracranial activity. Phase 1b trials ongoing with data updates expected in H2 2025 and Phase 3 trials planned for 2026.
As an emerging growth company, ORIC focuses on developing therapies targeting cancer resistance mechanisms in hormone-dependent cancers, precision oncology, and tumor dependencies.
Insider Trading Alert: Angie You, Director at Oric Pharmaceuticals (ORIC), has made significant stock purchases over two consecutive days in June 2025:
- June 20, 2025: Acquired 26,597 shares at weighted average price of $9.3871 per share
- June 23, 2025: Purchased additional 1,403 shares at $9.43 per share
Total position following these transactions: 28,000 shares held directly. The first purchase was executed across multiple price points ranging from $9.14 to $9.50. These direct market purchases by a director signal potential confidence in the company's prospects. The transactions were reported via Form 4 filing and executed through an attorney-in-fact, Christian Kuhlen.
The SEC has declared Oric Pharmaceuticals' Form S-3 registration statement effective as of June 20, 2025, at 4:00 P.M. The registration statement was filed under file number 333-287949.
Form S-3 is a shelf registration that allows publicly traded companies to register securities for future public offerings. This effectiveness notice indicates that Oric Pharmaceuticals has met SEC requirements and can now proceed with their planned securities offering(s).
This regulatory development suggests that Oric Pharmaceuticals may be positioning itself for potential future capital raising activities, which could include offerings of common stock, preferred stock, debt securities, warrants, or other securities as specified in their registration statement.